Liver Health Foods: 6 Essential Foods for Liver Function Improvement

This article highlights six foods that can help ease liver function: coffee, cruciferous vegetables, omega-3 fatty fish, nuts and extra-virgin olive oil, high-fiber pulses and whole grains, and fermented foods. These foods have been linked to lower liver enzymes, reduced fibrosis and cirrhosis risk, improved antioxidant defenses, healthier liver fat profiles, and better insulin sensitivity.

Roche has made a significant strategic acquisition by purchasing 89bio for up to $3.5 billion, marking the Swiss pharma giant's entry into the metabolic dysfunction-associated steatohepatitis (MASH) space Roche becomes MASH player via $3.5B deal for 89bio and its phase 3 drug^[1]. The deal centers around 89bio's phase 3 drug candidate, pegozafermin, a FGF21 analog in late-stage trials for MASH in patients with moderate to severe fibrotic conditions and cirrhosis of the liver.

The acquisition includes a cash payment of $14.50 per share, representing a 79% premium over 89bio's closing price the previous day. Additionally, shareholders will receive contingent value rights up to $6 per share, tied to certain milestones such as the first sale of pegozafermin to F4 MASH cirrhotic patients before March 31, 2030 Roche becomes MASH player via $3.5B deal for 89bio and its phase 3 drug^[1]. The total equity value of the deal is approximately $3.5 billion.

The integration of 89bio's employees into Roche's pharmaceuticals division is expected to complete in the fourth quarter of 2025. Roche CEO Thomas Schinecker emphasized that the acquisition strengthens its portfolio in cardiovascular, renal, and metabolic diseases, offering opportunities for combinations with existing programs in the pipeline Roche becomes MASH player via $3.5B deal for 89bio and its phase 3 drug^[1].

Pegozafermin's potential to become a transformative treatment option in MASH is driven by its combined anti-fibrotic and anti-inflammatory mechanism, which could offer best-in-disease efficacy for moderate to severe MASH patients Roche becomes MASH player via $3.5B deal for 89bio and its phase 3 drug^[1]. The deal reflects Roche's interest in the growing market for MASH treatments, which has seen recent advancements such as Madrigal Pharmaceuticals' FDA approval of Rezdiffra and Novo Nordisk's approval of Wegovy for the fatty liver disease Roche becomes MASH player via $3.5B deal for 89bio and its phase 3 drug^[1].

The MASH market has been heating up, with interest in FGF21 analogs growing since 2023, following promising phase 2b results from 89bio and Akero Therapeutics' efruxifermin Roche becomes MASH player via $3.5B deal for 89bio and its phase 3 drug^[1]. The FDA's consideration of a noninvasive liver measurement as a surrogate endpoint for certain MASH patients could further accelerate drug development in this area Roche becomes MASH player via $3.5B deal for 89bio and its phase 3 drug^[1].